Public list: BIO 2016 (619) Pharma Startups (6570)
Akebia Therapeutics is focused on discovering and developing therapeutic solutions leveraging the potential of the hypoxia-inducible factor - or HIF - biology. HIF-Prolyl Hydroxylase inhibition could represent an approach to treating certain conditi...Show all
Company (IPO / Went public)
Phone: 617-871-2098
245 First Street
Suite 1400
Cambridge, 02142
Massachusetts, United States
Total Funding | Date of Last Funding | |
---|---|---|
Akebia Therapeutics | $95.3M | Sep 1, 2017 |
Humanetics Corporation | $0.6M | Jul 23, 2020 |
Affinium Pharmaceuticals | $44.9M | Sep 12, 2013 |
See all 32 competitors |
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | Mar 13, 2019 | Aug 11, 2020 | Patent |
Prolyl hydroxylase inhibitors and methods of use | Aug 31, 2018 | Aug 04, 2020 | Patent |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 01, 2018 | Mar 24, 2020 | Patent |
Prolyl hydroxylase inhibitors and methods of use | Jan 19, 2018 | Jun 18, 2019 | Patent |
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | Aug 31, 2017 | Apr 02, 2019 | Patent |